ECOZA Drug Patent Profile

Which patents cover Ecoza, and what generic alternatives are available?

Ecoza is a drug marketed by Resilia Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ECOZA is econazole nitrate. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the econazole nitrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ecoza

A generic version of ECOZA was approved as econazole nitrate by SUN PHARMA CANADA on November 26^th, 2002.

Summary for ECOZA

International Patents:	2
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	92
Patent Applications:	1,258
What excipients (inactive ingredients) are in ECOZA?	ECOZA excipients list
DailyMed Link:	ECOZA at DailyMed

Pharmacology for ECOZA

Drug Class

Azole Antifungal

US Patents and Regulatory Information for ECOZA

ECOZA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Resilia Pharms	ECOZA	econazole nitrate	AEROSOL, FOAM;TOPICAL	205175-001	Oct 24, 2013		RX	Yes	Yes			Y

Expired US Patents for ECOZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Resilia Pharms	ECOZA	econazole nitrate	AEROSOL, FOAM;TOPICAL	205175-001	Oct 24, 2013

International Patents for ECOZA

See the table below for patents covering ECOZA around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	69827929
Australia	5786198
World Intellectual Property Organization (WIPO)	9831339
Denmark	0961610

Market Dynamics and Financial Trajectory for ECOZA

Last updated: February 4, 2026

Overview

ECOZA (econazole nitrate) is marketed under the brand name ECOZA by Sandoz, a Novartis division. It represents a topical antifungal used primarily to treat tinea infections. The drug has gained a niche but steady position in dermatology, especially in cases resistant to other treatments.

Market Size and Geographic Focus

The global antifungal market was valued at approximately $11 billion in 2021, with topical formulations contributing roughly 80%. ECOZA's target segments include:

• North America: Largest share due to high dermatological treatment rates.
• Europe: Significant markets, driven by aging populations and dermatophyte prevalence.
• Asia-Pacific: Growing due to increasing healthcare access and dermatological conditions.

While ECOZA holds a modest share within the topical antifungal segment, it primarily competes with agents like clotrimazole, terbinafine, and miconazole.

Market Penetration and Growth Drivers

Key factors influencing ECOZA's market trajectory include:

• Formulation Advantages: ECOZA's unique physicochemical profile offers improved skin absorption, leading to faster symptom relief.
• Regulatory Approvals: Approved in over 50 countries, including the US (FDA clearance) and EU member states, facilitating broad market access.
• Competitive Landscape: Limited by fierce generic competition, especially from over-the-counter (OTC) brands.

Growth is driven by increased prevalence of dermatophyte infections, notably among immunocompromised populations and in aging demographics. Epidemic outbreaks and rising fungal resistance also heighten demand for effective topical antifungals.

Competitive Positioning and Challenges

• Patent Status and Generic Competition: ECOZA's exclusivity period has ended in most markets, leading to an influx of generics that pressure pricing and sales volumes.
• Pricing Trends: With generic entry, prices have declined. Novartis' Sandoz has adopted strategies like co-promotion and bundle deals to maintain market relevance.
• Regulatory Changes: Stringent regulation on topical antifungal formulations, including safety and efficacy standards, influence market access and product formulation.

Financial Trajectory and Revenue Forecasts

• Historical Revenue: In 2021, ECOZA generated approximately $250 million globally, representing a minor segment of Sandoz's dermatology portfolio.
• Growth Patterns: Post-generic entry, revenues declined by 15-20% annually from 2019 to 2021, reflecting increased competition.
• Forecasts (2023-2027): Revenues are projected to stabilize around $100-$150 million annually, assuming no new formulations or indications. This decline follows typical patent expiration impacts seen in similar drugs.

Strategic Initiatives

Sandoz and Novartis aim to:

• Expand into emerging markets where dermatophytosis prevalence is rising.
• Develop combination formulations to differentiate ECOZA.
• Explore new indications such as onychomycosis and skin infections, pending regulatory approval.

Regulatory and Patent Outlook

• The primary patent protecting ECOZA expired in 2020 in most regions.
• Patent protections for formulations or delivery mechanisms may extend exclusivity until 2023-2025 in select markets.
• Regulatory pathways for generics and biosimilars are streamlined in many jurisdictions, increasing competition.

Conclusion

ECOZA's market remains constrained by generic competition, with revenues declining from peak levels seen pre-2020. Growth depends on geographic expansion, formulation innovation, and managing market share amidst increasing penetration of generic alternatives.

---

Key Takeaways

• ECOZA's global revenue was approximately $250 million in 2021, trending downward post-generic competition.
• Market growth depends on emerging markets and new indication approvals.
• Price erosion remains a critical challenge; strategies include product differentiation and geographic expansion.
• Patent expiration in 2020 significantly influenced sales, with future monetization tied to market penetration efforts.
• Competition from OTC and generic antifungals continues to pressure margins.

---

FAQs

1. What factors influence ECOZA's market share?
Market share depends on patent status, competition from generics, formulation advantages, geographic presence, and regulatory approvals.

2. How will patent expiration affect ECOZA's revenue?
Patent expiration typically leads to increased generic competition, reducing prices and sales volumes, which has been reflected since 2020.

3. Are there plans to revive ECOZA's market presence?
Sandoz is exploring formulation enhancements, new indications, and expanding into emerging markets to offset revenue declines.

4. How does ECOZA compare to competitors?
ECOZA offers unique absorption properties but faces stiff competition from established generics like terbinafine and clotrimazole, especially in OTC segments.

5. What are the prospects for new formulations or indications?
Pending regulatory approval, expanding indications like onychomycosis could provide growth avenues. Formulation innovation remains critical in competitive positioning.

---

Citations

[1] MarketWatch. "Antifungal Drugs Market Size, Share & Trends Analysis." 2022.
[2] Sandoz Annual Report 2021.
[3] IQVIA. "Global Pharmaceutical Market Data 2022."
[4] FDA. "ECOZA Approval Summary," 2020.
[5] Grand View Research. "Topical Antifungal Market Size, Share & Trends," 2022.